Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

BACKGROUND: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). METHODS: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: Vandenberghe, Rik, Rinne, Juha O., Boada, Mercè, Katayama, Sadao, Scheltens, Philip, Vellas, Bruno, Tuchman, Michael, Gass, Achim, Fiebach, Jochen B., Hill, Derek, Lobello, Kasia, Li, David, McRae, Tom, Lucas, Prisca, Evans, Iona, Booth, Kevin, Luscan, Gerald, Wyman, Bradley T., Hua, Lisa, Yang, Lingfeng, Brashear, H. Robert, Black, Ronald S.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4866415/
https://ncbi.nlm.nih.gov/pubmed/27176461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0189-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados